The Journal of Clinical Psychiatry

Page 577

More JCP Articles

Original Research

A Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Adjunctive Paroxetine in Panic Disorder Patients Unsuccessfully Treated With Cognitive-Behavioral Therapy Alone

September 23, 2002

Mirjam Kampman , Ger P. J. Keijsers , Cees A. L. Hoogduin , et al

Letter to the Editor

Reply to Letter to the Editor “Injection of Depot Antipsychotic Medications in Patients With Schizophrenia”

September 23, 2002

Yuval Bloch

Book Review

School Violence: Assessment, Management, Prevention

September 23, 2002

Robert J. Harmon

Book Review

In Search of Madness: Schizophrenia and Neuroscience

September 23, 2002

Henry A. Nasrallah

Original Research

Subsyndromal Depression Is Associated With Functional Impairment in Patients With Bipolar Disorder

September 23, 2002

Lori L. Altshuler , Michael J. Gitlin , Jim Mintz , et al

Book Review

Traumatic Relationships and Serious Mental Disorders

September 23, 2002

John C. Racy

Letter to the Editor

Venlafaxine in a Patient With Idiopathic Leukopenia and Mirtazapine-Induced Severe Neutropenia

September 23, 2002

Ion Anghelescu , Christoph Klawe , Norbert Dahmen

Original Research

Venlafaxine Treatment of Binge-Eating Disorder Associated With Obesity: A Series of 35 Patients

September 23, 2002

Shishuka Malhotra , Karen H. King , Jeffrey A. Welge , et al

Article

Assessing Cardiovascular Risks Versus Clinical Benefits of Atypical Antipsychotic Drug Treatment

September 1, 2002

Herbert Y. Meltzer , Michael Davidson , Alexander H. Glassman , et al

Article

Clinical Management of Cardiovascular Risks During Treatment With Psychotropic Drugs

September 1, 2002

Alexander Glassman

Article

Introduction: Cardiovascular and Metabolic Risks Associated With Schizophrenia and Antipsychotic Drug Treatment

September 1, 2002

Herbert Y. Meltzer

Article

Mechanisms and Risks of Electrocardiographic QT Interval Prolongation When Using Antipsychotic Drugs

September 1, 2002

W. Victor R. Vieweg

« 1 … 575 576 577 578 579 … 758 »

A Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Adjunctive Paroxetine in Panic Disorder Patients Unsuccessfully Treated With Cognitive-Behavioral Therapy Alone

Reply to Letter to the Editor “Injection of Depot Antipsychotic Medications in Patients With Schizophrenia”

School Violence: Assessment, Management, Prevention

In Search of Madness: Schizophrenia and Neuroscience

Subsyndromal Depression Is Associated With Functional Impairment in Patients With Bipolar Disorder

Traumatic Relationships and Serious Mental Disorders

Venlafaxine in a Patient With Idiopathic Leukopenia and Mirtazapine-Induced Severe Neutropenia

Venlafaxine Treatment of Binge-Eating Disorder Associated With Obesity: A Series of 35 Patients

Assessing Cardiovascular Risks Versus Clinical Benefits of Atypical Antipsychotic Drug Treatment

Clinical Management of Cardiovascular Risks During Treatment With Psychotropic Drugs

Introduction: Cardiovascular and Metabolic Risks Associated With Schizophrenia and Antipsychotic Drug Treatment

Mechanisms and Risks of Electrocardiographic QT Interval Prolongation When Using Antipsychotic Drugs

ELSEWHERE:

FOLLOW US:

More JCP Articles

A Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Adjunctive Paroxetine in Panic Disorder Patients Unsuccessfully Treated With Cognitive-Behavioral Therapy Alone

Reply to Letter to the Editor “Injection of Depot Antipsychotic Medications in Patients With Schizophrenia”

School Violence: Assessment, Management, Prevention

In Search of Madness: Schizophrenia and Neuroscience

Subsyndromal Depression Is Associated With Functional Impairment in Patients With Bipolar Disorder

Traumatic Relationships and Serious Mental Disorders

Venlafaxine in a Patient With Idiopathic Leukopenia and Mirtazapine-Induced Severe Neutropenia

Venlafaxine Treatment of Binge-Eating Disorder Associated With Obesity: A Series of 35 Patients

Assessing Cardiovascular Risks Versus Clinical Benefits of Atypical Antipsychotic Drug Treatment

Clinical Management of Cardiovascular Risks During Treatment With Psychotropic Drugs

Introduction: Cardiovascular and Metabolic Risks Associated With Schizophrenia and Antipsychotic Drug Treatment

Mechanisms and Risks of Electrocardiographic QT Interval Prolongation When Using Antipsychotic Drugs

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles